Arbutus Biopharma (NASDAQ:ABUS) Stock Rating Lowered by StockNews.com

Arbutus Biopharma (NASDAQ:ABUS) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Thursday.

ABUS has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Arbutus Biopharma in a research report on Tuesday, January 21st. Chardan Capital reissued a “buy” rating and issued a $5.00 price objective (up previously from $4.50) on shares of Arbutus Biopharma in a research note on Wednesday, November 20th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $5.50.

Arbutus Biopharma Stock Performance

Shares of ABUS stock opened at $3.30 on Thursday. Arbutus Biopharma has a 1 year low of $2.30 and a 1 year high of $4.73. The stock has a fifty day moving average of $3.33 and a two-hundred day moving average of $3.62. The firm has a market capitalization of $625.32 million, a PE ratio of -7.67 and a beta of 1.93.

Institutional Trading of Arbutus Biopharma

Several large investors have recently made changes to their positions in ABUS. E Fund Management Co. Ltd. acquired a new position in Arbutus Biopharma in the 4th quarter valued at approximately $34,000. Xponance Inc. bought a new position in Arbutus Biopharma in the 4th quarter valued at $34,000. Raymond James Financial Inc. bought a new position in shares of Arbutus Biopharma in the 4th quarter worth $34,000. Cibc World Markets Corp acquired a new position in Arbutus Biopharma in the fourth quarter valued at about $45,000. Finally, Hsbc Holdings PLC acquired a new position in Arbutus Biopharma in the fourth quarter valued at about $55,000. Institutional investors own 43.79% of the company’s stock.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.